Dr. Phil Kearney joined Merck Sharp & Dohme Australia in 2007 as the key scout for innovative research and development in Australia, New Zealand and some parts of South East Asia. The Sydney-born scientist has the challenge of uncovering and commercialising discoveries by local researchers that have strong potential to benefit the health of people around the globe.
Prior to joining Merck, Phil spent 7 years in small to medium biotech companies in Scandinavia. Phil held project and executive management positions in Active Biotech Research (Sweden) and Santaris Pharma (Denmark) during this time.
Before leaving Australia he had been the head of the Research Laboratory in one of Australia’s leading Haematology Departments, at St Vincent’s Hospital Sydney for over 10 years. The theme of the laboratory was antisense and ribozyme mediated ablation of bcr-abl expression in Chronic Myeloid Leukaemia. As an adjunct position Phil also ran the Molecular Medicine Diagnostic Laboratory for the hospital pathology service, SydPath.
Phil holds a Ph.D. from Monash University, which was followed by post-doctoral training at the Murdoch Institute in Melbourne and University College London. He also holds an MBA from the University of Sydney.